Somatic mutation dynamics in MDS patients treated with azacitidine indicate clonal selection in patients-responders.

about

Somatic mutation dynamics in MDS patients treated with azacitidine indicate clonal selection in patients-responders.

Item

http://www.wikidata.org/entity/Q47562352

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Somatic mutation dynamics in M ...... ection in patients-responders.

@en

Somatic mutation dynamics in M ...... ection in patients-responders.

@nl

type

Item

label

Somatic mutation dynamics in M ...... ection in patients-responders.

@en

Somatic mutation dynamics in M ...... ection in patients-responders.

@nl

prefLabel

Somatic mutation dynamics in M ...... ection in patients-responders.

@en

Somatic mutation dynamics in M ...... ection in patients-responders.

@nl

P1476

Somatic mutation dynamics in M ...... ection in patients-responders.

@en

P2093

Anna Jonasova

http://www.w3.org/2001/XMLSchema#string

Kamila Polgarova

http://www.w3.org/2001/XMLSchema#string

Lubomir Minarik

http://www.w3.org/2001/XMLSchema#string

Nina Dusilkova

http://www.w3.org/2001/XMLSchema#string

Tomas Stopka

http://www.w3.org/2001/XMLSchema#string

Vojtech Kulvait

http://www.w3.org/2001/XMLSchema#string

Zuzana Zemanova

http://www.w3.org/2001/XMLSchema#string

P2860

Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes.

The Sequence Alignment/Map format and SAMtools

Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence

Clinical effect of point mutations in myelodysplastic syndromes

Mechanisms of resistance to decitabine in the myelodysplastic syndrome.

Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation

TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients

Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia.

Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia.

Stem and progenitor cells in myelodysplastic syndromes show aberrant stage-specific expansion and harbor genetic and epigenetic alterations

P304

111966-111978

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.22957

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Karin Vargova

Michal Pesta

P577

2017-12-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29340104

http://www.w3.org/2001/XMLSchema#string

P932

5762372

http://www.w3.org/2001/XMLSchema#string